(PMGMU) – Corporate News
-
AEON Biopharma (AEON) Presents Positive Results from Phase 2 Clinical Trial of ABP-450 (prabotulinumtoxinA) in Cervical Dystonia
-
AEON Biopharma (AEON) Receives Notice of Allowance from USPTO for a Patent Covering Use of Botulinum Toxins to Treat Migraine Headache
-
Back to PMGMU Stock Lookup
